Brief: TCR2 Therapeutics Reports Fourth Quarter And Full-Year 2022 Financial Results
23/03/2023 10:34
March 23 (Reuters) - Tcr2 Therapeutics Inc TCRR.O :
* TCR² THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR
2022
FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* TCR2 THERAPEUTICS - FOLLOWING EXPECTED Q2 2023 CLOSING OF
ALL-STOCK DEAL WITH ADAPTIMMUNE COMBINED CO'S CASH RUNWAY IS
EXPECTED TO EXTEND INTO 2026
* STRATEGIC COMBINATION WITH ADAPTIMMUNE TO CREATE A
PREEMINENT
CELL THERAPY C FOCUSED ON TREATING SOLID TUMORS
* QTRLY NET LOSS PER SHARE OF COMMON STOCK, BASIC AND
DILUTED
$1.56
* Q4 EARNINGS PER SHARE VIEW $-0.79 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX4VlV81
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview